Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes
Diabetes Technology & Therapeutics · 2025
DOI: 10.1089/dia.2024.0328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, 2025. Verfasst von Janet K Snell-Bergeon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glucagon-Like Peptides, Glycated Hemoglobin, Hypoglycemic Agents. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
Adults with type 1 diabetes (T1D) are increasingly overweight or obese, in part due to intensive insulin therapy. Newer non-insulin medications targeting both hyperglycemia and weight loss are approved for people with type 2 diabetes. These drugs also reduce cardiovascular disease, the major cause of mortality in people with diabetes. We assessed the real-world use of semaglutide and tirzepatide, in adults with T1D followed in a specialty diabetes clinic. Materials and Methods: This retrospective chart review included 100 adults who were prescribed semaglutide or tirzepatide (50 each) and 50 controls frequency matched for age, sex, diabetes duration, body mass index, and glycosylated hemoglobin (HbA1c) and who did not receive any weight loss medications during the study period. Data were collected prior to initiation of weight loss medications (baseline) and then for up to 1 year for each patient.
Results
Matching characteristics did not differ between cases and controls. There were declines in weight in both semaglutide (−19.2 ± standard error (SE) 2.9 lbs. [9.1% body weight lost]) and tirzepatide (−49.4 ± SE 3.0 lbs. [21.4% body weight lost]) groups, and HbA1c decreased in both semaglutide (−0.54 ± SE 0.14%, P = 0.0001) and tirzepatide users (−0.68 ± SE 0.16%, P < 0.0001) over 12 months. Weight and HbA1c didn’t change in controls.
Conclusions
We observed weight loss of 9.1% and 21.4% and improved glucose control in semaglutide and tirzepatide users, respectively, after 1 year of off-label use. As off-label use of these drugs is increasing in patients with T1D, larger, prospective safety and efficacy trials are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado, USA.
ORCID-Profile: Janet K Snell-Bergeon, Halis K Akturk
Zitieren
APA
Snell-Bergeon, J. K., Kaur, G., Renner, D., Akturk, H. K., Beatson, C., & Garg, S. K. (2025). Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2024.0328
Vancouver
Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics. 2025. doi:10.1089/dia.2024.0328
BibTeX
@article{SnellBergeon2025,
author = {Snell-Bergeon, Janet K and Kaur, Gurleen and Renner, Drew and Akturk, Halis K and Beatson, Christie and Garg, Satish K},
title = {Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes},
journal = {Diabetes Technology & Therapeutics},
year = {2025},
doi = {10.1089/dia.2024.0328}
}
EUVIMED